CA3065316A1 - Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease - Google Patents

Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Download PDF

Info

Publication number
CA3065316A1
CA3065316A1 CA3065316A CA3065316A CA3065316A1 CA 3065316 A1 CA3065316 A1 CA 3065316A1 CA 3065316 A CA3065316 A CA 3065316A CA 3065316 A CA3065316 A CA 3065316A CA 3065316 A1 CA3065316 A1 CA 3065316A1
Authority
CA
Canada
Prior art keywords
ctc
cancer
ctcs
patient
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065316A
Other languages
English (en)
French (fr)
Inventor
Ryan DITTAMORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epic Sciences Inc
Original Assignee
Epic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epic Sciences Inc filed Critical Epic Sciences Inc
Publication of CA3065316A1 publication Critical patent/CA3065316A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3065316A 2017-06-02 2018-06-01 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending CA3065316A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762514642P 2017-06-02 2017-06-02
US62/514,642 2017-06-02
US201762531725P 2017-07-12 2017-07-12
US62/531,725 2017-07-12
PCT/US2018/035581 WO2018222979A1 (en) 2017-06-02 2018-06-01 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease

Publications (1)

Publication Number Publication Date
CA3065316A1 true CA3065316A1 (en) 2018-12-06

Family

ID=64455086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065316A Pending CA3065316A1 (en) 2017-06-02 2018-06-01 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease

Country Status (8)

Country Link
US (2) US20220260574A1 (https=)
EP (1) EP3631445B1 (https=)
JP (2) JP2020522697A (https=)
CN (1) CN110998318A (https=)
AU (1) AU2018275265A1 (https=)
CA (1) CA3065316A1 (https=)
IL (1) IL270974A (https=)
WO (1) WO2018222979A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225753A2 (en) * 2019-05-06 2020-11-12 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113826169A (zh) * 2019-05-14 2021-12-21 匹兹堡大学高等教育联邦体系 用于根据多参数细胞和亚细胞成像数据表征细胞表型多样性的系统和方法
WO2021108043A1 (en) * 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
AU2021207312A1 (en) * 2020-01-17 2022-06-30 Universität Zürich Single cell pathology analysis of tumour samples
CN114092934A (zh) * 2020-07-31 2022-02-25 骏实生物科技(上海)有限公司 循环肿瘤细胞的分类方法
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用
JP7836038B2 (ja) * 2020-12-10 2026-03-26 国立大学法人信州大学 メラノーマ患者の治療効果を判定する方法
US20240054640A1 (en) * 2020-12-15 2024-02-15 Carnegie Mellon University System, Method, and Computer Program Product for Classification of Diseases Based on Expansion Microscopic Images
EP4060319A1 (en) 2021-03-12 2022-09-21 Sysmex Corporation Analysis method and analyzer
JP7824031B2 (ja) * 2021-03-12 2026-03-04 シスメックス株式会社 分析方法および分析装置
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2920317A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US20160266127A1 (en) 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3100052B1 (en) * 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3303363A4 (en) * 2015-05-29 2019-01-23 Epic Sciences, Inc. INTRAPATIENT GENOMHETEROGENICITY OF INDIVIDUAL CIRCULATIVE TUMOR CELLS (CTCS) RELATED TO PHENOTYPIC CTC HETEROGENICITY IN METASTASED, CASTING RESISTANT PROSTATE CANCER (MCRPC)

Also Published As

Publication number Publication date
CN110998318A (zh) 2020-04-10
EP3631445A1 (en) 2020-04-08
JP2020522697A (ja) 2020-07-30
EP3631445B1 (en) 2024-09-25
US20220260574A1 (en) 2022-08-18
EP3631445A4 (en) 2021-05-26
AU2018275265A1 (en) 2020-01-30
WO2018222979A1 (en) 2018-12-06
US20250155440A1 (en) 2025-05-15
JP2023120213A (ja) 2023-08-29
IL270974A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20220390451A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20250155440A1 (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
US20240103003A1 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
US20230033449A1 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
US20200333345A1 (en) Circulating tumor cell diagnostics for prostate cancer biomarkers
US20250180564A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230511

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241018

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507